HK1103720A1 - Thiazole derivatives and use thereof - Google Patents

Thiazole derivatives and use thereof

Info

Publication number
HK1103720A1
HK1103720A1 HK07105602A HK07105602A HK1103720A1 HK 1103720 A1 HK1103720 A1 HK 1103720A1 HK 07105602 A HK07105602 A HK 07105602A HK 07105602 A HK07105602 A HK 07105602A HK 1103720 A1 HK1103720 A1 HK 1103720A1
Authority
HK
Hong Kong
Prior art keywords
diseases
thiazole derivatives
neturodegenerative
prophylaxis
transplantation
Prior art date
Application number
HK07105602A
Other languages
English (en)
Inventor
Anna Quattropani
Thomas Rueckle
Matthias Schwarz
Jerome Dorbais
Wolfgang Sauer
Christophe Cleva
Gwenaelle Desforges
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of HK1103720A1 publication Critical patent/HK1103720A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
HK07105602A 2004-01-12 2007-05-28 Thiazole derivatives and use thereof HK1103720A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04100083 2004-01-12
PCT/EP2005/050102 WO2005068444A2 (fr) 2004-01-12 2005-01-11 Derives thiazole et utilisation de ces derives

Publications (1)

Publication Number Publication Date
HK1103720A1 true HK1103720A1 (en) 2007-12-28

Family

ID=34778214

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07105602A HK1103720A1 (en) 2004-01-12 2007-05-28 Thiazole derivatives and use thereof

Country Status (26)

Country Link
US (2) US8802861B2 (fr)
EP (1) EP1709019B1 (fr)
JP (1) JP5290524B2 (fr)
KR (1) KR101260521B1 (fr)
CN (1) CN1926121B (fr)
AT (1) ATE369349T1 (fr)
AU (1) AU2005205201B2 (fr)
BR (1) BRPI0506749A (fr)
CA (1) CA2551415C (fr)
CY (1) CY1106921T1 (fr)
DE (1) DE602005001931T2 (fr)
DK (1) DK1709019T3 (fr)
EA (1) EA012328B1 (fr)
ES (1) ES2287896T3 (fr)
HK (1) HK1103720A1 (fr)
HR (1) HRP20070357T3 (fr)
IL (1) IL176764A (fr)
NO (1) NO20063606L (fr)
NZ (1) NZ548197A (fr)
PL (1) PL1709019T3 (fr)
PT (1) PT1709019E (fr)
RS (1) RS50521B (fr)
SI (1) SI1709019T1 (fr)
UA (1) UA83099C2 (fr)
WO (1) WO2005068444A2 (fr)
ZA (1) ZA200605624B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
BRPI0517253A (pt) * 2004-10-28 2008-10-07 Irm Llc compostos e composições como moduladores de trajetória de ouriço
AU2006251157B2 (en) 2005-05-24 2011-09-01 Merck Serono Sa Thiazole derivatives and use thereof
EP1741709A1 (fr) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Amides heterocycliques substitués contenant un linker saturé, et leur utilisation comme agent pharmaceutique
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
AU2007210159A1 (en) * 2006-01-26 2007-08-09 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
MX2009008798A (es) * 2007-02-22 2009-08-24 Syngenta Participations Ag Derivados de iminipiridina y sus usos como microbicidas.
EP2572712A3 (fr) 2007-06-01 2013-11-20 The Trustees Of Princeton University Traitement d'infections virales par modulation de voies métaboliques de cellules hôtes
CA2693473A1 (fr) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazoles modulateurs de l'activite de pkb
EP2173728A2 (fr) 2007-07-17 2010-04-14 Amgen Inc. Modulateurs hétérocycliques de pkb
WO2009051909A1 (fr) * 2007-10-16 2009-04-23 The Regents Of The University Of California Composés présentant une activité de correction du traitement cellulaire cftr mutante, et utilisations de ceux-ci
JP2011506563A (ja) * 2007-12-20 2011-03-03 ノバルティス アーゲー ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
CN102471351A (zh) 2009-07-02 2012-05-23 诺瓦提斯公司 用作pi3k抑制剂的2-羧酰胺环氨基脲
EP2492269A4 (fr) 2009-10-19 2013-08-07 Taisho Pharmaceutical Co Ltd Dérivé de l'aminothiazole
WO2012068209A2 (fr) 2010-11-18 2012-05-24 Janssen Pharmaceutica Nv Inhibiteurs bisthiazole de l'activation de métalloprotéinases de matrice
US20120302573A1 (en) 2011-05-25 2012-11-29 Paul Francis Jackson Methods of inhibiting pro matrix metalloproteinase activation
EP2727032A2 (fr) 2011-06-29 2014-05-07 Janssen Pharmaceutica, N.V. Méthodes de conception, de sélection et/ou d'optimisation d'inhibiteurs de traitement allostériques pour métalloprotéinases matricielles
CA2840202A1 (fr) 2011-06-29 2013-01-03 Janssen Pharmaceutica Nv Structure cristalline de la proforme d'une metalloproteinase matricielle et inhibiteur de maturation allosterique
CA2840393A1 (fr) * 2011-06-29 2013-01-03 Janssen Pharmaceutica Nv Methodes de traitement utilisant des inhibiteurs de maturation allosteriques pour metalloproteinases matricielles
JPWO2015046193A1 (ja) 2013-09-25 2017-03-09 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
WO2015048633A2 (fr) * 2013-09-30 2015-04-02 The Texas A&M University System Compositions associées et procédés de gestion de déplacement de neutrophiles
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
EP3811940B1 (fr) * 2019-10-22 2023-05-10 Kemijski Institut 4,5'-bithiazoles substitués comme inhibiteurs de la topoisomérase ii de l'adn humain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649146A (en) * 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
SE9302332D0 (sv) 1993-07-06 1993-07-06 Ab Astra New compounds
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
JPH11209284A (ja) 1998-01-27 1999-08-03 Sagami Chem Res Center 骨形成促進剤
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
WO2001083481A1 (fr) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'imidazopyridine
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
DE60208630T2 (de) * 2001-05-11 2006-08-17 Pfizer Products Inc., Groton Thiazolderivate und ihre Verwendung als cdk-Inhibitoren
PE20030968A1 (es) 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
BRPI0517253A (pt) * 2004-10-28 2008-10-07 Irm Llc compostos e composições como moduladores de trajetória de ouriço

Also Published As

Publication number Publication date
DK1709019T3 (da) 2007-10-01
US9150561B2 (en) 2015-10-06
JP5290524B2 (ja) 2013-09-18
ES2287896T3 (es) 2007-12-16
US20090029998A1 (en) 2009-01-29
AU2005205201A1 (en) 2005-07-28
NZ548197A (en) 2010-06-25
KR20060128975A (ko) 2006-12-14
ZA200605624B (en) 2007-11-28
CA2551415A1 (fr) 2005-07-28
SI1709019T1 (sl) 2007-10-31
AU2005205201B2 (en) 2011-05-12
US8802861B2 (en) 2014-08-12
EP1709019B1 (fr) 2007-08-08
PL1709019T3 (pl) 2007-10-31
DE602005001931T2 (de) 2008-04-24
JP2007517835A (ja) 2007-07-05
ATE369349T1 (de) 2007-08-15
IL176764A0 (en) 2006-10-31
PT1709019E (pt) 2007-08-27
DE602005001931D1 (de) 2007-09-20
WO2005068444A3 (fr) 2005-09-09
IL176764A (en) 2011-06-30
HRP20070357T3 (en) 2007-10-31
UA83099C2 (en) 2008-06-10
CN1926121A (zh) 2007-03-07
CA2551415C (fr) 2013-09-10
CN1926121B (zh) 2012-06-13
EA200601242A1 (ru) 2007-02-27
BRPI0506749A (pt) 2007-05-22
EP1709019A2 (fr) 2006-10-11
RS50521B (sr) 2010-05-07
CY1106921T1 (el) 2012-09-26
NO20063606L (no) 2006-10-12
WO2005068444A2 (fr) 2005-07-28
US20140228365A1 (en) 2014-08-14
KR101260521B1 (ko) 2013-05-06
EA012328B1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
HK1103720A1 (en) Thiazole derivatives and use thereof
UA96735C2 (en) Thiazole derivatives and use thereof
UA93374C2 (en) Thiazole derivatives and use thereof
HK1106773A1 (en) Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
UA100358C2 (xx) Похідні піразину та їх застосування
MX2009009031A (es) Compuestos de quinoxalina y uso de los mismos.
RS115904A (en) Azolidinone-vinyl fused benzene derivatives
TW200616968A (en) Compound having basic substituent and application thereof
SG163517A1 (en) Antiviral compounds and methods
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
SE0302304D0 (sv) Novel compounds
DE502005007472D1 (de) Desoxo-nonadepsipeptide
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
UA88314C2 (en) Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
SE0200119D0 (sv) Novel compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160111